Ventyx Biosciences (NasdaqGS:VTYX) Earnings Call Presentation

Phase 2 Trial of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors Topline Results October 22, 2025 Forward Looking Statements Ventyx Biosciences, Inc. ("Ventyx" or the "Company") cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the pote ...